When Should Preoperative Radiochemotherapy Be Performed?

  • Claus Rödel
  • Vincenzo Valentini
  • Bruce D. Minsky


There are two general approaches to preoperative radiotherapy (RT) in rectal cancer: short-course (25 Gy in five fractions) RT with immediate surgery (i.e., within 10 days of the first fraction of RT) and long-course 5-fluorouracil-based radiochemotherapy (RCTx, 1.8–2.0 Gy per fraction over 5–6 weeks, for a total dose of 45–50.4 Gy) with surgery scheduled approximately 6 weeks thereafter. Both approaches have been shown to improve locoregional tumor control compared with surgery alone [1]. Whereas short-course RT is mainly used in Northern Europe, conventionally fractionated RT with concurrent fluoropyrimidine chemotherapy is the current standard treatment in Southern Europe and the United States. Patients selected for treatment with short-course RT historically include those with cT1-3 disease, whereas those selected for RCTx include cT3-4 and/or cN+ disease. Two randomized trials of short-course RT vs. RCTx have included patients with cT3 and/or cN+ disease.


  1. 1.
    Minsky BD, Rödel C, Valentini V (2012) Short-course radiation versus long-course chemoradiation for rectal cancer. J Natl Compr Cancer Netw 10:1223–1231CrossRefGoogle Scholar
  2. 2.
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215–1223CrossRefPubMedGoogle Scholar
  3. 3.
    Ngan SY, Burmeister B, Fisher RJ et al (2012) Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: trans-Tasman radiation oncology group trial 01.04. J Clin Oncol 30:3827–3833CrossRefPubMedGoogle Scholar
  4. 4.
    Minsky BD, Valentini V (2014) MRI-based treatment decision making for rectal cancer. Oncology. 28:680–681. Williston ParkGoogle Scholar
  5. 5.
    Braendengen M, Tveit KM, Berglund A et al (2008) Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 26:3687–3694CrossRefPubMedGoogle Scholar
  6. 6.
    Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740CrossRefPubMedGoogle Scholar
  7. 7.
    Sloothaak DA, Geijsen DE, van Leersum NJ et al (2013) Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 100:933–939CrossRefPubMedGoogle Scholar
  8. 8.
    Pettersson D, Cedermark B, Holm T et al (2010) Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 97:580–587CrossRefPubMedGoogle Scholar
  9. 9.
    Rödel C, Hofheinz R, Liersch T (2012) Rectal cancer: state of the art in 2012. Curr Opin Oncol 24:441–447CrossRefPubMedGoogle Scholar
  10. 10.
    Fernandez-Martos C, Garcia-Albeniz X, Pericay C et al (2015) Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol 26:1722–1728CrossRefPubMedGoogle Scholar
  11. 11.
    Garcia-Aguilar J, Chow OS, Smith DD et al (2015) Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 16:957–966CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  • Claus Rödel
    • 1
  • Vincenzo Valentini
    • 2
  • Bruce D. Minsky
    • 3
  1. 1.Department of Radiotherapy and OncologyUniversity of FrankfurtFrankfurtGermany
  2. 2.Department of Radiation Oncology, Largo A.Gemelli 8 00168Università Cattolica S CuoreRomeItaly
  3. 3.Department of Radiation Oncology, The University of TexasMD Anderson Cancer Center, HoustonTexasUSA

Personalised recommendations